Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) was downgraded by equities researchers at Barclays PLC from an “overweight” rating to an “equal weight” rating in a note issued to investors on Thursday. They presently have a $50.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $85.00. Barclays PLC’s target price points to a potential upside of 45.90% from the company’s current price.
A number of other equities analysts have also issued reports on the company. Credit Suisse Group AG set a $145.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, September 30th. FBR & Co reissued an “outperform” rating and issued a $180.00 price objective on shares of Alnylam Pharmaceuticals in a report on Sunday, July 17th. Jefferies Group reissued a “buy” rating and issued a $80.00 price objective (down from $119.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, June 8th. Zacks Investment Research lowered Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 25th. Finally, Morgan Stanley initiated coverage on Alnylam Pharmaceuticals in a report on Tuesday, August 2nd. They issued an “overweight” rating and a $93.00 price objective for the company. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $80.88.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.27 on Thursday. The stock has a 50 day moving average price of $70.69 and a 200-day moving average price of $66.05. The firm’s market capitalization is $2.94 billion. Alnylam Pharmaceuticals has a 12-month low of $33.16 and a 12-month high of $110.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The business earned $8.70 million during the quarter, compared to analyst estimates of $8.09 million. During the same period in the prior year, the company posted ($0.85) EPS. The business’s revenue for the quarter was up .2% compared to the same quarter last year. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post ($4.68) EPS for the current year.
In other news, CEO John Maraganore sold 30,151 shares of the stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now owns 148,465 shares in the company, valued at $9,604,200.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.00% of the stock is owned by insiders.
Hedge funds have recently made changes to their positions in the company. Altrinsic Global Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at about $4,250,000. AXA raised its stake in shares of Alnylam Pharmaceuticals by 50.5% in the first quarter. AXA now owns 98,689 shares of the biopharmaceutical company’s stock valued at $6,195,000 after buying an additional 33,116 shares in the last quarter. State Street Corp raised its stake in shares of Alnylam Pharmaceuticals by 15.7% in the first quarter. State Street Corp now owns 1,936,520 shares of the biopharmaceutical company’s stock valued at $121,553,000 after buying an additional 262,783 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Alnylam Pharmaceuticals by 348.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,321 shares of the biopharmaceutical company’s stock valued at $836,000 after buying an additional 10,348 shares in the last quarter. Finally, Credit Agricole S A raised its stake in shares of Alnylam Pharmaceuticals by 11.6% in the first quarter. Credit Agricole S A now owns 12,182 shares of the biopharmaceutical company’s stock valued at $765,000 after buying an additional 1,270 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.